Lyngby Latest News (Copenhagen, Denmark)

MonTa Biosciences, a Copenhagen-based clinical-stage biotech company developing next-generation innate immune modulators for cancer therapy, today announced the expansion of its clinical program with MBS8, a second-generation TLR7 agonist

Chip Interfaces, a leading provider of high-performance chip-to-chip interface IP cores, is contributing significantly to EXTOLL's collaboration with Eridan in the development of Eridan's next-generation ASIC.